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Background: Several studies have identified L1CAM as a strong prognostic marker in 
endometrial cancer. To further underline the clinical usefulness of this biomarker, we 
investigated L1CAM as a predictive marker for lymph node metastases and its prognostic 
impact in curettage specimens and preoperative plasma samples. In addition we aimed to 
validate the prognostic value of L1CAM in hysterectomy specimen. 
Methods: Immunohistochemical staining of L1CAM was performed for 795 hysterectomy 
and 1134 curettage specimen from endometrial cancer patients. L1CAM level in preoperative 
blood samples from 372 patients was determined using ELISA.  
Results: Expression of L1CAM in curettage specimen was significantly correlated to L1CAM 
level in corresponding hysterectomy specimen (P<0.001). Both in curettage and preoperative 
plasma samples was L1CAM upregulation significantly associated with features of aggressive 
disease and poor outcome (P<0.001). L1CAM was an independent predictor of lymph node 
metastases, after correction for curettage histology, both in curettage specimen (P=0.002) and 
plasma samples (P=0.048). In the hysterectomy samples L1CAM was significantly associated 
with poor outcome (P<0.001). 
Conclusions: We demonstrate that preoperative evaluation of L1CAM levels, both in 
curettage or plasma samples, predicts lymph node metastases and adds valuable information 
on patient prognosis.  
 
 





Endometrial cancer is the most common gynaecologic malignancy and the fourth most 
common cancer among women in industrialized countries (Torre et al, 2015). Although the 
prognosis is good, fifteen to twenty percent of patients with presumed localized disease at 
diagnosis recur (Abeler & Kjorstad, 1991; Morrow et al, 1991). Identifying biomarkers that 
can select patient populations for optimal surgical and systemic treatment is important to 
improve outcome for these patients.  
The diagnosis and treatment of endometrial cancer patients usually consists of a preoperative 
biopsy followed by imaging, surgery and adjuvant treatment depending on risk classification. 
A complete surgical staging of endometrial cancer patients involves both pelvic and para-
aortic lymphadenectomy (Pecorelli, 2009). Worldwide there are however a wide variation in 
lymphadenectomy in endometrial cancer, and selection criteria for lymphadenectomy are not 
uniformly standardized (Maggino et al, 1998; Maggino et al, 1995). Metastases to the lymph 
nodes is known to be associated with poor prognosis and although lymphadenectomy 
provides diagnostic information that can help in selecting optimal adjuvant treatment, its 
effect on survival is uncertain, and it is associated with increased complication rates 
(Benedetti Panici et al, 2008; Morice et al, 2016; Wright et al, 2012). Improved identification 
of high-risk patients preoperatively is therefore needed to tailor the primary surgical strategy. 
L1 cell adhesion molecule (L1CAM) is a cell adhesion molecule of the immunoglobulin 
superfamily (Moos et al, 1988). L1CAM consists of an extracellular domain, a 
transmembrane region and a highly conserved cytoplasmic domain (Moos et al, 1988). The 
extracellular domain of L1CAM can be cleaved by the metalloproteases ADAM10 and 
ADAM17 resulting in a soluble form of L1CAM (Maretzky et al, 2005; Mechtersheimer et al, 
2001). L1CAM was initially identified in the nervous system, and plays an important role in 
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neurogenesis (Moos et al, 1988; Rathjen & Schachner, 1984; Schafer & Altevogt, 2010). 
Later L1CAM has also been shown to be involved in almost every aspect of cancer 
progression including promoting cell proliferation, migration, invasion and metastases of 
cancer cells (Altevogt et al, 2016; Raveh et al, 2009; Schafer & Altevogt, 2010).  
Expression of L1CAM has been investigated in several cancer types, and is associated with 
poor outcome (Allory et al, 2005; Boo et al, 2007; Fogel et al, 2003; Hua et al, 2016; 
Schroder et al, 2009; Tischler et al, 2011; Tsutsumi et al, 2011; Wang et al, 2013). In 
endometrial cancer hysterectomy samples, L1CAM has been reported to be associated with 
aggressive disease characteristics including loss of hormone receptors and reduced survival 
(Bosse et al, 2014; Dellinger et al, 2016; Geels et al, 2016; Huszar et al, 2010; Kommoss et 
al, 2017; van der Putten et al, 2016; Zeimet et al, 2013). L1CAM is a strong prognostic 
marker within the subgroup of stage I endometrioid endometrial cancer (van der Putten et al, 
2016; Zeimet et al, 2013), and within the subgroup of advanced stage endometrioid 
endometrial cancer (van der Putten et al, 2016), when evaluated postoperatively in 
hysterectomy samples. However, the expression of L1CAM in preoperative biopsies and its 
usefulness in preoperative prediction of lymph node metastases and outcome are not yet 
established. Also soluble L1CAM (sL1CAM) is suggested to be a valuable circulating 
biomarker in different cancers (Bondong et al, 2012; Zander et al, 2011). It has been detected 
in the culture medium from different cell lines including melanoma, breast and ovarian cancer 
(Beer et al, 1999; Gutwein et al, 2005; Li & Galileo, 2010), and also in serum and ascites of 
endometrial and ovarian cancer (Fogel et al, 2003; Wojciechowski et al, 2017), suggesting 
that also the soluble form of L1CAM may play a role in these cancers. 
The primary objective of this study was to assess the value of L1CAM in preoperative 
samples (curettage and plasma samples) as a predictive marker for lymph node metastases and 
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poor prognosis. In addition we aimed to validate the prognostic value of L1CAM in 
hysterectomy samples. 
MATERIALS AND METHODS 
Patient series 
A population-based series was prospectively collected from 2001 to 2014 and included 
curettage specimen (n=600), primary tumours (n=795, of which 189 overlapped with cases 
published by van der Putten et al.(van der Putten et al, 2016)) and plasma (n=372) from 
patients diagnosed with endometrial cancer in Hordaland County (Norway). Within the 
MoMaTEC study (Molecular markers in treatment of Endometrial Cancer, NCT00598845) 
nine other centres contributed with preoperative biopsies from in total 534 patients treated for 
endometrial cancer prospectively included at their institutions. Formalin-fixed, paraffin-
embedded (FFPE) tumour tissue from curettage specimen was collected from all participating 
institutions (Trovik et al, 2013). Clinical and histopathological data was collected, including 
age, FIGO stage (according to 2009 criteria), histologic type and grade and myometrial 
invasion from hysterectomy specimen. Follow up data were collected as previously described 
(Trovik et al, 2011). Preoperative histology reports were categorized as high risk (serous, 
clear cell, carcinosarcoma, undifferentiated carcinomas, endometrioid grade 3) or low risk 
(benign (diagnosed with endometrial cancer after hysterectomy), hyperplasia, endometrioid 
grade 1-2). Pelvic lymphadenectomy as part of surgical staging was conducted in the majority 
of cases (n=825 73%), of these additional para-aortic lymph node sampling was conducted for 
6% (n=49). Fresh frozen tissue from hysterectomy samples was investigated for L1CAM 
mRNA expression in 232 patients, these overlapped with FFPE samples. 
The study has been approved by Norwegian legislation, including the Norwegian Data 
Inspectorate, Norwegian Social Science Data Services and the Western Regional Committee 
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for Medical and Health Research Ethics (REK 2009/2315). All patients signed informed 
consent prior to inclusion in the study. 
Immunohistochemical staining 
FFPE tissue from curettage and hysterectomy samples were available in TMAs from 1134 and 
795 patients respectively, for evaluation of L1CAM level. Tissue microarrays (TMA) were 
generated from FFPE tissue as previously described, with three tissue cylinders from each 
case (Stefansson et al, 2004). TMAs were dewaxed in xylene and rehydrated in graded 
ethanol series before microwave boiling in target retrieval buffer (pH9) for 15 minutes. 
L1CAM was detected using purified anti-CD171 (L1) antibody clone 14.10 (Biolegend, San 
Diego, CA, USA) diluted 1:100 for 60 minutes at room temperature, followed by 30 minutes 
incubation with secondary HPR-conjugated antibody. Diaminobenzidine was applied for 8 
minutes before counterstained with haematoxylin. All slides were scored independently and 
blinded for clinical and pathological data by two authors using standard light microscopy. 
Inter-evaluator Kappa value was calculated to be 0.76 for L1CAM in two groups. The 
staining was evaluated as previously described (Engelsen et al, 2008). Briefly, both intensity 
and area of positive tumour cells were considered. The intensity of staining was graded from 
0 (no staining) to 3 (strong), and the area from 0, 1 (< 10 %), 2 (10-50%) and 3 (51-100%). 
From this, a staining index (0-9) was calculated as the product of intensity and area. If 
heterogeneity was seen for the three tissue cylinders of each case, the three cylinders were 
given one overall averaged score. In subsequent statistical analysis indexes were grouped 
according to similarity in survival and considering the size of the subgroup and the number of 
events in each category. For L1CAM index 0-3 was considered low and 4-9 high 
(Supplementary Figure 1). Immunohistochemical (IHC) staining and staining evaluation of 
ER and PR has previously been described (Trovik et al, 2013). Using the same scoring system 




EDTA-blood was obtained from 372 patients with endometrial cancer before primary surgery. 
The blood samples were centrifuged at 1600 g for 15 minutes and the plasma was stored at -
80oC until measurement of sL1CAM. ELISA kits were bought from MyBioSource (Cat. No. 
MBS2023094, MyBioSource, San Diego, CA, USA) and the sandwich ELISA was performed 
according to the manufacturer´s instructions. Briefly, 100 μl plasma sample or standard was 
put into a 96-well microplate and incubated for two hours at 37oC. Then, 100 μl biotin-
conjugated L1CAM specific antibody was added and incubated for 1 hour at 37°C. After the 
well was washed three times with washing solution, 100 μl avidin conjugated to horseradish 
peroxidase (HRP) was added and incubated for 30 minutes at 37°C. The wells were washed 
five times and 90 μl substrate solution was added before 20 minutes incubation away from 
light followed by addition of 50 μl stop solution. The absorbance was measured in a 
microplate reader at the wavelength of 450 nm, and plasma concentration of sL1CAM 
calculated. For further statistical analysis the patients were grouped in four groups based on 
sL1CAM plasma level, and subsequently in high and low L1CAM based on similarities in 
survival (the three groups with lowest L1CAM level=low L1CAM level; the upper 
quartile=high L1CAM level) (Supplementary Figure 1). Plasma from healthy aged-matched 
female blood-donors (n=32) was used as control group. 
Gene expression analysis 
RNA was extracted from fresh frozen tissue from primary tumour from patients diagnosed 
with endometrial cancer. Hybridization to Agilent Whole Human Genome Microarray 44k 
(Cat. No. G4112F) was done according to the manufacturer´s instructions. The arrays were 




Data were analysed using SPSS version 24 (SPSS Inc, Chicago, IL). Probability <0.05 was 
considered statistical significant, and all statistical tests were two-sided. Associations between 
groups were analysed using the chi-square test for categorical variable and the Mann-Whitney 
U test for continuous variables. Binary logistic regression was used to estimate odds ratios 
(OR) for lymph node metastases. Univariate survival analysis was performed using the 
Kaplan Meier (product-limit) method. Disease specific survival was defined as time from 
surgery to death from endometrial cancer. Survival between groups was compared using the 
log-rank (Mantel-Cox) test. The Cox proportional hazard regression model was used to 
evaluate the prognostic impact of L1CAM adjusted for other prognostic parameters.  
RESULTS 
Expression of L1CAM in endometrial cancer curettage predicts lymph node metastases 
and poor outcome.  
L1CAM protein expression was evaluated by IHC in curettage samples from 1134 patients. 
Low expression was defined as staining index 0-3 and was found in 88% (n=1000) of the 
lesions, while 12% (n=134) expressed high levels of L1CAM. High L1CAM expression in 
curettage specimen was significantly associated with high age, loss of ER and PR expression 
and high-risk curettage classification and also high FIGO stage, non-endometrioid histology 
and high grade in the hysterectomy specimen, (all P<0.001) (Table 1). There was a highly 
significant correlation between L1CAM staining in curettage specimen and staining in the 
corresponding hysterectomy specimen (P<0.001) (Table 1). High expression of L1CAM in 
curettage specimen predicted poor disease specific survival both in the whole patient 
population (P<0.001) (Figure 1A), and within patients with low risk curettage histology 
(P<0.001) (Figure 1B). Expression of L1CAM also showed independent prognostic impact in 
Cox survival analysis after correction for age, FIGO stage, histologic subtype and grade 
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assessed in the hysterectomy specimens, with hazard ratio of 1.77 (95% CI 1.17-2.66, 
P=0.006) (Supplementary Table 1).   
 
Interestingly, patients with high L1CAM expression in curettage specimen had significantly 
higher occurrence of lymph node metastases compared to patients with low expression of 
L1CAM, both in the whole patient population (33% vs. 10% respectively, P<0.001, Table 1), 
and in the subgroup with low risk histology classification (30% vs. 9% respectively, P<0.001, 
Supplementary Table 2). In a univariate model, curettage high-risk histology, combined loss 
of ER/PR (a marker previously shown to be a strong predictor of lymph node metastases in 
endometrial cancer patients (Trovik et al, 2013)), and high expression of L1CAM all 
predicted presence of metastatic lymph nodes (Table 2). When adjusting for curettage 
histology and preoperative ER/PR loss in a multivariate model, high expression of L1CAM 
predicted lymph node metastases with adjusted OR 2.51 (95% CI 1.41-4.64, P=0.002) (Table 
2). 
High sL1CAM level in preoperative blood samples is associated with lymph node 
metastases and poor survival in endometrial cancer patients. 
The level of sL1CAM was also investigated in preoperative plasma samples from 372 patients 
with endometrial cancer. The plasma level of sL1CAM was significantly higher in 
endometrial cancer patients compared to healthy controls (P=0.001 (endometrial cancer 
patients: mean=997 pg/ml, SEM=27; healthy controls mean=684 pg/ml, SEM=29)). There 
was a significant correlation between sL1CAM level in plasma evaluated by ELISA, and 
L1CAM expression both in curettage specimen (P=0.007) (Supplementary Figure 2A) and 
hysterectomy specimen (P=0.015) (Supplementary Figure 2B) evaluated by IHC. High 
preoperative plasma levels of sL1CAM were significantly associated with high age, loss of 
ER and PR and high-risk histology in curettage, and also high FIGO stage and non-
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endometrioid histology in the hysterectomy specimen (Table 3). High sL1CAM plasma level 
predicted poor disease specific survival both in the whole population (P<0.001) (Figure 1C) 
as well as in the group with low-risk curettage histology (P=0.04) (Figure 1D).  sL1CAM 
level in plasma did not have independent prognostic impact when adjusting for age, FIGO 
stage, histologic type and grade (data not shown).  
Patients with high sL1CAM plasma levels had significantly higher occurrence of lymph node 
metastases compared to patients with low sL1CAM level (23% vs. 9% respectively, P=0.003) 
when including the whole patent population, but not within the subgroup with low risk 
histology classification (Supplementary table 2).  In a univariate model both high-risk 
histology in curettage and high plasma levels of sL1CAM were predictive of lymph node 
metastases. Also when correcting for curettage histology in a multivariate model, sL1CAM 
level in plasma was a predictor of lymph node metastases with OR 2.25 (95% CI 1.01-5.02, 
P=0.048) (Table 4).  
Expression of L1CAM in hysterectomy specimen validates to be a strong predictor of 
poor outcome in endometrial cancer. 
Several studies have identified L1CAM as a strong prognostic marker when examining 
hysterectomy specimens in endometrial cancer. In this study we investigated expression of 
L1CAM in 795 primary tumours. In 14% of the cases (n=110) expression of L1CAM was 
high while 86% (n=685) of the cases showed low L1CAM levels. There was a significant 
association between L1CAM protein levels and L1CAM mRNA levels (Supplementary 
Figure 3). We identified that high expression of L1CAM in hysterectomy samples is 
associated with features of aggressive endometrial cancer (Supplementary Table 3) and poor 
survival (Figure 1E). Expression of L1CAM also showed independent prognostic impact in 
Cox survival analysis when adjusting for age, FIGO stage, histologic subtype and grade with 
HR 2.7 (95% CI 1.8-4.3, P<0.001) (Supplementary Table 4). Within the subgroup of stage I 
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endometrioid endometrial cancer 5% of the cases expressed high L1CAM. Also within this 
subgroup expression of L1CAM was associated with characteristics of aggressive endometrial 
cancer (Supplementary Table 5) and poor survival (Figure 1F), but it did not have 
independent prognostic impact when adjusting for age and histologic grade (data not shown).  
DISCUSSION 
There are several studies suggesting L1CAM as a promising biomarker in endometrial cancer, 
and its expression has earlier been shown to be associated with aggressive disease and poor 
survival, and inversely correlated with expression of ER and PR (Bosse et al, 2014; Dellinger 
et al, 2016; Geels et al, 2016; Huszar et al, 2010; Kommoss et al, 2017; van der Putten et al, 
2016; Zeimet et al, 2013). Current data points to an added prognostic value of L1CAM, and 
integrating L1CAM status as part of the molecular classification of endometrial cancer can be 
useful. We here validate that L1CAM is a strong prognostic marker in hysterectomy samples 
when including all samples in this prospectively collected population-based series. Also 
within the subgroup of patients with FIGO stage 1 endometrioid endometrial cancer, L1CAM 
expression is a predictor of poor survival, although not as strong as shown in other studies 
(van der Putten et al, 2016; Zeimet et al, 2013). The usefulness of L1CAM as a prognostic 
marker within this subgroup was also questioned in a recent study including 388 patients 
where L1CAM failed to be a clinically relevant marker of poor prognosis in FIGO stage 1 
endometrioid endometrial cancer (Smogeli et al, 2016). These differences could be explained 
by different scoring methods and cut-offs for L1CAM, but also differences in the patient 
cohort with regard to proportion of patients where lymphadenectomy is performed, as well as 
the use of adjuvant treatment.  
In this study TMAs were used to determine the expression of L1CAM, and the staining index 
was used as scoring method with high expression defined as 4-9 and low expression defined 
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as 0-3. Most other studies investigating the expression of L1CAM have used whole sections 
and a cut-off point of 10% (Bosse et al, 2014; Smogeli et al, 2016; van der Putten et al, 2016; 
Zeimet et al, 2013). The use of different scoring methods and cut-offs make the studies less 
comparable, however the fact that different scoring methods identifies L1CAM as a strong 
biomarker supports its robustness as biomarker in endometrial cancer. Although a 
interobserver κ-value of 0.76 was obtained for L1CAM in this study a scoring method like the 
staining index where both intensity and area is taken into account may be more subjectively 
influenced compared to the method only considering the area. Before potential clinical 
implementation of L1CAM as biomarker in endometrial cancer, the optimal staining protocol, 
scoring method and cut-off will have to be determined and validated. In an investigational 
setting the use of TMAs is both time and cost effective, and the method has been shown to 
yield reproducible results compared to full sections (Fons et al, 2007; Kononen et al, 1998). 
TMAs do however not provide the same morphological information as full sections, and 
should be used with caution, and depending on the research question. Although three tissue 
cores were used for each patient in this study, L1CAM positive areas of the tumor might be 
missed, which may result in underestimation of L1CAM expression. This is however also a 
challenge using full sections, and validation of markers is crucial before applied in a clinical 
setting.  
In endometrial cancer the tumour is easily accessible for biopsy prior to surgery. Histologic 
type and grade are routinely investigated in the preoperative biopsies, and this provides 
prognostic information relevant for the extent of the surgery. However the correlation 
between preoperative assessment of curettage and postoperative evaluation of hysterectomy 
specimens varies (Eltabbakh et al, 2005; Frumovitz et al, 2004; Lampe et al, 1995; Leitao et 
al, 2008; Werner et al, 2013). Therefore, identification of reliable markers in curettage 
material that could predict lymph node metastases would provide a better basis for treatment 
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selection. There are different molecular markers that have been studied in preoperative 
biopsies, and could serve as predictive markers for metastatic disease (Salvesen et al, 2012). 
One example is combined loss of ER and PR for prediction of lymph node metastases and 
poor survival in endometrial cancer (Trovik et al, 2013). Its usefulness in tailoring surgical 
treatment is currently tested in a clinical trial (Momatec2, NCT02543710), where the decision 
to perform lymphadenectomy in low and intermediate risk patients is dependent of the 
preoperative hormone receptor status. In the present study we investigate L1CAM level in 
curettage and preoperative blood samples, and its potential for predicting lymph node 
metastases and poor prognosis. Only few studies have previously investigated the expression 
of L1CAM in curettage samples. Bosse et al. (Bosse et al, 2014) compared expression of 
L1CAM in curettage and hysterectomy samples from 42 patients and Fogel et al. (Fogel et al, 
2003) from 14 patients. Both studies reported a good concordance between staining in 
curettage and hysterectomy samples (Bosse et al, 2014; Fogel et al, 2003). We here confirm 
that the L1CAM staining in the curettage and hysterectomy sample are significantly 
associated. More importantly, we report the novel finding that high L1CAM expression in 
curettage samples is a significant predictor of lymph node metastases, both in a univariate 
analysis and in a multivariate analysis correcting for curettage histology and preoperative 
ER/PR expression. Our large study shows that L1CAM expression in curettage specimens is 
associated with features of aggressive endometrial cancer disease and poor survival both in 
the whole patient population and within the subgroup of patients with a preoperative low-risk 
histology classification. These findings suggest that evaluation of L1CAM in curettage 
samples could be a valuable supplement to the currently performed preoperative assessment 
for determination of surgical extent. However, this is the first study investigating L1CAM as a 
predictive marker for lymph node metastases and its prognostic impact in curettage 
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specimens, and these findings would have to be validated in other studies before its place in 
the preoperative assessment can be determined.  
The soluble form of L1CAM has earlier shown to be present in sera of endometrial cancer 
patients. In a study by Fogel et. al. nine out of ten patients with L1CAM positive endometrial 
tumours also had detectable concentrations of sL1CAM in preoperative serum samples (Fogel 
et al, 2003). A recent study investigating serum levels of sL1CAM in 35 endometrial cancer 
patients found it to be lower in patients compared to healthy controls, and no correlations 
between soluble L1CAM concentration and histopathology, stage or grade were found 
(Wojciechowski et al, 2017). The latter is contradictory to our results as we find that the level 
of sL1CAM is significantly increased in endometrial cancer patients compared to healthy 
controls, and that a high level of sL1CAM is associated with aggressive disease 
characteristics, and poor survival. In addition we report that a high level of sL1CAM in 
preoperative blood samples predicts of lymph node metastasis both in a univariate analysis, 
and also multivariate analysis correcting for preoperative histology. Increased level of 
sL1CAM has been found to be associated with poor prognosis also in other cancer types, such 
as in gastrointestinal stromal tumours (Zander et al, 2011) and ovarian cancer (Bondong et al, 
2012). Whether the soluble form of L1CAM also in addition to serving as a prognostic 
biomarker, has a role in tumour development and progression is not clear, but studies 
investigating its function have suggested that sL1CAM is involved in stimulating cell motility 
and contribute to cell survival through activating anti apoptotic pathways (Bondong et al, 
2012; Mechtersheimer et al, 2001).     
The primary treatment for endometrial cancer patients is surgical, which typically includes 
hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy. 
Although lymphadenectomy is part of the complete staging procedure and important for risk 
stratification of endometrial cancer patients, no survival benefit is shown in randomized 
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clinical trials, and it is associated with increased complication rates and prolonged operation 
time in a co-morbid and obese patient population (Benedetti Panici et al, 2008; Morice et al, 
2016; Pecorelli, 2009; Wright et al, 2012). Identifying markers that preoperatively can predict 
prognosis and lymph node metastases is important. Biomarkers can aid in tailoring the 
surgical treatment through identifying those patients with advanced disease who would 
benefit from extensive surgery, but also aid in preventing over-treatment in low-risk patients. 
Both L1CAM expression evaluated by IHC in curettage and the level of sL1CAM evaluated 
by ELISA in plasma seem to be promising biomarkers in endometrial cancer. Although 
L1CAM expression in curettage is a stronger predictor of both lymph node metastases and 
disease specific survival in multivariate analysis compared to sL1CAM in plasma, and may be 
the preferred method, the fact that no tissue, only a blood sample is necessary for the 
sL1CAM analysis is an advantage. However, additional studies and in particular prospective 
randomized trials would be important to evaluate the effect of implementing L1CAM 
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Figure 1. Expression of L1CAM is a prognostic marker in curettage samples, blood 
samples and hysterectomy samples of endometrial cancer patients.  
High expression of L1CAM in curettage samples was significantly associated with poor 
outcome, in the whole patient population (A), and in the subgroup of patients with low-risk 
histology in curettage (B). In plasma from endometrial cancer patients high level of L1CAM 
was predictive of poor outcome both in the whole patient population (C) and in the subgroup 
of patients with low-risk histology in curettage (D). High expression of L1CAM in 
hysterectomy samples is significantly associated with poor survival, both in the whole 
population (E), and in the subgroup with stage 1 endometrioid endometrial cancer (F). * 
Curettage histological risk classification, low risk (benign, hyperplasia or endometrioid grades 
1-2) or high risk (non-endometrioid or endometrioid grade 3). Number in brackets: number of 
patients in the group/number of events in the group. 
 
Supplementary Figure 1. Disease specific survival according to staining index and 
sL1CAM level.  
L1CAM expression was scored using the staining index, and high staining index was 
significantly associated with poor disease specific survival (A). Patients were grouped in four 
groups based in sL1CAM plasma level, and the group with high sL1CAM level had 
significantly poorer survival compared to the groups with intermediate and low sL1CAM 
levels (B).  
 
Supplementary Figure 2. Correlation between L1CAM protein and plasma levels. 
Protein expression of L1CAM investigated by IHC in curettage (A) and hysterectomy (B) 




Supplementary Figure 3. Correlation between L1CAM protein and mRNA levels. 
In hysterectomy samples there is a significant correlation between protein levels of L1CAM 
investigated by IHC and L1CAM mRNA levels. 

Variable Low (0-3) n (%) High (4-9) n (%) P -value
Age <0.001
<66 520 (95) 30 (5)
≥66 480 (82) 104 (18)
Information available preoperatively
Curettage histology* <0.001
Low risk 811 (95) 40 (5)
High risk 170 (64) 94(36)
PR curettage <0.001
Positive 795 (96) 36 (4)
Negative 191 (69) 88(31)
ERα curettage <0.001
Positive 746 (95) 43 (5)
Negative 228 (72) 89 (28)
Information available postoperatively
FIGO-09 stage <0.001
I-II 872 (91) 84 (9)
III-IV 128 (72) 50 (28)
Histologic type <0.001
Endometrioid 874 (96) 36 (4)
Adenosquamous 10 (91) 1 (9)
Clear cell 29 (71) 12 (29)
Serous papillary 39 (36) 70 (64)
Carcinosarcoma 35 (76) 11 (24)
Undifferentiated/other 13 (77) 4 (23)
Histologic grade** <0.001
Grade 1/2 754 (97) 21 (3)
Grade 3 120 (86) 19 (14)
Metastatic nodes <0.001
Negative 657 (92) 60 (8)
Positive 77 (72) 30 (28)
Myometrial infiltration <0.001
<50% 608 (92) 51 (8)
≥50% 309 (84) 60 (16)
Ploidy <0.001
Diploid 288 (94) 17 (6)
Aneuploid 49 (58) 35 (42)
L1CAM hysterectomy specimen <0.001
Low 431 (96) 16 (4)
High 26 (36) 46 (64)
**only endometrioid
Table 1. Clinico-pathological variables related to L1CAM status in curettage 
specimens for women operated for endometrial cancer
*Curettage histological risk classification, low risk (benign, hyperplasia or 
endometrioid grades 1-2) or high risk (non-endometrioid or endometrioid grade 3).
Missing information on curettage histology classification for 19 patients, PR status in 
curettage for 24 patients, ERα status in curettage for 28 patients, grade for 9 
patients, metastatic nodes for 310 patients, myometrial infiltration for 106 patients, 





95% CI P Multi-
variate 
OR






Low-risk 590 1 1
High-risk 173 3.39 2.19-5.23 <0.001 1.94 1.16-3.25 0.011 0.49 0.75 0.22 0.91
L1CAM expression
Low 681 1 1
High 82 4.49 2.69-7.50 <0.001 2.51 1.41-4.64 0.002 0.28 0.92 0.33 0.90
ER/PR expression
Normal 606 1 1
Loss*** 157 3.26 2.10-5.07 <0.001 1.91 1.15-3.17 0.013 0.42 0.82 0.26 0.90
Table 2. Prediction of lymph node metastases based on curettage histology, status of 
L1CAM and ER/PR in curettage specimen in 763 lymph node sampled endometrial cancer 
patients.
* Only patients with data available for all variables included in the multivariate logistic regression 
analysis are included in the univariate analysis (N=763).
** Curettage histological classification, low risk (benign, hyperplasia or endometrioid grades 1-2) or 
high risk (non-endometrioid or endometrioid grade 3).
*** Patients with double loss of ER/PR expression.
Variable Low n (%) High n (%) P -value
Age <0.001
<66 165 (89) 20 (11)
≥66 116 (62) 71 (38)
Information available preoperatively
Curettage histology* <0.001
Low risk 217 (80) 54 (20)
High risk 58 (62) 36 (38)
PR curettage 0.027
Positive 160 (81) 37 (20)
Negative 37 (67) 18 (33)
ERα curettage 0.023
Positive 157 (81) 37 (19)
Negative 38 (67) 19 (33)
Information available postoperatively
FIGO-09 stage <0.001
I-II 252 (80) 61 (20)
III-IV 29 (49) 30 (51)
Histologic type <0.001
Endometrioid 238 (80) 61 (20)
Adenosquamous 4 (100) 0 (0)
Clear cell 9 (75) 3 (25)
Serous papillary 18 (55) 15 (45)
Carcinosarcoma 10 (59) 7 (41)
Undifferentiated/other 2 (29) 5 (71)
Histologic grade** 0.95
Grade 1/2 192 (80) 48 (20)
Grade 3 47 (80) 12 (20)
Metastatic nodes 0.003
Negative 225 (83) 44 (17)
Positive 22 (63) 13 (37)
Myometrial infiltration 0.027
<50% 175 (80) 42 (20)
≥50% 106 (71) 44 (29)
Ploidy 0.15
Diploid 145 (78) 42 (22)
Aneuploid 31 (67) 15 (33)
Table 3. Clinico-pathological variables related to sL1CAM 
status in preoperative blood samples from women treated 
for endometrial cancer
sL1CAM
* curettage histological risk classification, low risk (benign, 
hyperplasia or endometrioid grades 1-2) or high risk (non-
endometrioid or endometrioid grade 3).
**only endometrioid
Missing information on curettage histology classification for 7 
patients, PR status in curettage for 120 patients, ERα status in 
curettage for 121 patients, grade for 4 patients, metastatic nodes 
for 68 patients, myometrial infiltration for 5 patients and ploidy for 
139 patients.
Variable N* Univariate 
OR




Low-risk 224 1 1
High-risk 75 5.83 2.79-12.22 <0.001 5.21 2.46-11.06 <0.001
sL1CAM blood level
Low 242 1 1
High 57 2.96 1.38-6.31 0.005 2.25 1.01-5.02 0.048
Table 4. Prediction of lymph node metastases based on curettage histology, and status for 
sL1CAM in preoperative blood samples in 299 lymph node sampled endometrial cancer 
patients. 
* Only patients with data available for all variables included in the multivariate logistic regression 
analysis are included in the univariate analysis (N=299).
** Curettage histological risk classification, low risk (benign, hyperplasia or endometrioid grades 1-
2) or high risk (non-endometrioid or endometrioid grade 3).
